Relapse rate after treatment with ruxolitinib/ruxolitinib cream

Ruxolitinib/Ruxolitinib cream has shown significant efficacy in the treatment of atopic dermatitis (AD) and vitiligo, but the recurrence rate after treatment still needs to be treated with caution. The likelihood of relapse is closely related to individual patient differences, the severity of the condition, and the use of medications.

In general, ruxolitinib cream improves the symptoms of vitiligo by regulating the immune system's overreaction. During initial treatment, many patients are able to recover their skin pigment and gradually reduce their white spots. However, vitiligo is essentially an immune system disease, so even if treated with ruxolitinib cream, some patients may still experience recurrence after treatment.

According to some clinical studies, although most patients can achieve good results in the early stages of treatment, some patients' vitiligo symptoms may return once they stop using ruxolitinib cream, especially those with a longer course or a stronger immune system response.

The recurrence rate is related to many factors, including the status of the patient's immune system, changes in living environment, and the presence of other predisposing factors (such as mood swings, ultraviolet exposure, etc.). Some patients may experience a return of vitiligo after stopping the drug, while others may maintain treatment effects long-term. Therefore, patients should maintain close contact with their doctors during the treatment process, regularly evaluate the treatment effects, and adjust the treatment plan under the guidance of their doctors.

In conclusion, although ruxolitinib cream has significant efficacy in treating vitiligo, the problem of recurrence rate still exists. To reduce the risk of recurrence, patients should follow their doctor's recommendations during treatment, maintain continuity of treatment, and take appropriate nursing measures.

Reference: https://www.opzelura.com/